 CryoLife, Inc. NYSE: CRY CryoLife or the Company, a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of 100 million aggregate principal amount of 4.250 convertible senior notes due 2025 the Notes in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. CryoLife also granted the initial purchaser of the Notes an option to purchase, within a 13-day period, beginning on, and including, the date on which the Notes are first issued, up to an additional 15 million aggregate principal amount of the Notes. The sale of the Notes to the initial purchaser is expected to settle on June 23, 2020, subject to customary closing conditions, and CryoLife estimates that it will receive approximately 96.5 million in net proceeds or 111.1 million if the initial purchaser exercises its option to purchase additional Notes in full after deducting fees and estimated expenses payable by CryoLife. 